In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Medicis gains rights to Ipsen's botulium toxin Type A

Executive Summary

Ipsen has agreed to license Medicis (aesthetic treatments for dermatological and podiatric conditions) development, distribution, and marketing rights to its botulinum toxin Type A in the US, Canada, and Japan for relaxing frown lines and crow's feet around a patient's eyes.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register